本文選題：卵巢癌 + 紫杉醇��； 參考：《腫瘤防治研究》2017年04期

【摘要】：目的研究卵巢癌患者化療后,紫杉醇(PTX)血藥濃度與療效及不良反應(yīng)的相關(guān)性。方法75例卵巢癌患者接受PT方案(紫杉醇+卡鉑)一線化療。于每周期PTX靜脈輸注開始后(24±6)h采集靜脈血2次,采用膠乳免疫比濁法檢測PTX濃度。根據(jù)PTX血藥濃度的平均值,將75例患者分為≤25 h組、(26~30)h組和≥31 h組,回顧性分析PTX血藥濃度與療效及與不良反應(yīng)間的相關(guān)性。結(jié)果≤25 h組、(26~30)h組、≥31 h組PTX血藥濃度分別為(22.54±2.04)h、(28.62±1.87)h、(33.01±2.84)h,差異有統(tǒng)計學(xué)意義(P0.05)。隨著PTX血藥濃度的升高,化療的不良反應(yīng)發(fā)生率增多,程度加強(P0.05)。(26~30)h組的有效率(31.25%)高于≤25 h組(20%)(P=0.02),與≥31 h組有效率(33.33%)相比差異無統(tǒng)計學(xué)意義(P=0.96)。結(jié)論卵巢癌采用紫杉醇PTX血藥濃度在(26~30)h的患者療效好,且不良反應(yīng)稍低。
[Abstract]:Objective to study the correlation between plasma concentration of paclitaxel PTX and therapeutic effect and adverse reaction after chemotherapy in patients with ovarian cancer. Methods 75 patients with ovarian cancer were treated with PT regimen (paclitaxel carboplatin). Venous blood was collected twice at 24 鹵6 hours after each cycle of PTX infusion, and the concentration of PTX was detected by latex immunoturbidimetry. According to the average blood drug concentration of PTX, 75 patients were divided into two groups: group 鈮，

本文編號：1989415